Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Velimir A. Luketic, Juan F. Gallegos‐Orozco et al.|Gastroenterology|2016Cited by 1k
The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroidsAlexandre Louvet, Philippe Mathurin|Hepatology|2007Cited by 721
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary CholangitisChristophe Corpechot, Raoul Poupon, Olivier Chazouillères et al.|New England Journal of Medicine|2018Cited by 605
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS StudyJosep M. Llovet, Joong‐Won Park, Thomas Decaens et al.|Journal of Clinical Oncology|2013Cited by 596
Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis deltaDominique Roulot, Sophie Hillaire, Ségolène Brichler et al.|Journal of Hepatology|2020Cited by 151